KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clorox (CLX) Cash & Equivalents (2016 - 2025)

Clorox (CLX) has 17 years of Cash & Equivalents data on record, last reported at $227.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents changed N/A year-over-year to $227.0 million; the TTM value through Dec 2025 reached $227.0 million, changed N/A, while the annual FY2025 figure was $167.0 million, 17.33% down from the prior year.
  • Cash & Equivalents reached $227.0 million in Q4 2025 per CLX's latest filing, up from $167.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $518.0 million in Q3 2023 and bottomed at $167.0 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $286.0 million, with a median of $234.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 63.38% in 2021, then surged 100.55% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $210.0 million in 2021, then soared by 32.38% to $278.0 million in 2022, then increased by 27.7% to $355.0 million in 2023, then plummeted by 43.1% to $202.0 million in 2024, then grew by 12.38% to $227.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $227.0 million in Q4 2025, $167.0 million in Q2 2025, and $226.0 million in Q1 2025.